Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 1;81(1):167-175.
doi: 10.1093/cid/ciae642.

Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis

Christine A Tzelios  1 , Samantha Malatesta  2 , Tara Carney  3   4 , Laura F White  2 , Sarah E Weber  5 , Sarah Thomson  6 , Danie Theron  7 , Bronwyn Myers  3   4   8 , Charles D H Parry  3   4 , Robin M Warren  9 , C Robert Horsburgh  10 , Maha R Farhat  1   11 , Karen R Jacobson  6
Affiliations

Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis

Christine A Tzelios et al. Clin Infect Dis. .

Abstract

Background: Adverse drug reactions (ADRs) to tuberculosis (TB) medications make treatment completion challenging. We investigated the impact of alcohol, human immunodeficiency virus (HIV), and other patient determinants on ADRs and treatment adherence.

Methods: We administered monthly ADR questionnaires to participants with TB in Worcester, South Africa. Adherence was defined as the proportion of observed doses on days when directly observed therapy was attempted. We used regression modeling to identify associations between age, sex, HIV status, alcohol, and smoked substance use with ADRs and adherence.

Results: Of 286 participants, 70 (24.5%) had moderate alcohol use (phosphatidylethanol [PEth], 20-200 ng/mL), 81 (28.3%) had heavy alcohol use (PEth, >200 ng/mL), and 81 (28.3%) had HIV. A total of 156 (54.5%) reported ≥1 ADR, with maximum severity of moderate (75.6%) or mild (22.4%). Alcohol use and HIV were not associated with ADRs. The presence of ≥1 comorbidity compared with none was associated with a 46% increase in the risk of ADRs (P = .01). Nearly 70% of participants had ≥80% adherence. Among participants with moderate or severe ADRs, HIV with CD4 count <200 cells/µL compared with no HIV (rate ratio = 1.71, P = .01), moderate or severe alcohol use compared with low (rate ratio = 1.55, P = .01 and rate ratio = 1.69, P = .01), and smoked substance use compared with none (rate ratio = 1.37, P = .04) were associated with increased missed doses.

Conclusions: Half of participants on TB treatment experienced ADRs, but most remained adherent to treatment. Among participants with moderate or severe ADRs, those with poorly controlled HIV, alcohol use, or smoked substance use had lower adherence.

Keywords: Adverse drug reactions; Alcohol; HIV; Treatment adherence; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

    1. World Health Organization. Global tuberculosis report 2023. Available at: https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf.... Accessed 1 December 2024.
    1. Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007; 11:868–75. - PubMed
    1. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4:e238. - PMC - PubMed
    1. Tola HH, Tol A, Shojaeizadeh D, Garmaroudi G. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review. Iran J Public Health 2015; 44:1–11. - PMC - PubMed
    1. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5:231–49. - PubMed

Substances